References
1.(WHO) WHO. Weekly epidemiological update on COVID-19, May 2022.
2.Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child & Adolescent Health. 2020 2020/09/01/;4(9):653-61.
3.Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. Pediatrics. 2022;149(1).
4.Williams P, Koirala A, Saravanos G, Lopez L, Glover C, Sharma K, et al. COVID-19 in children in NSW, Australia, during the 2021 Delta outbreak: Severity and Disease spectrum. medRxiv. 2021.
5.Delahoy MJ, Ujamaa D, Whitaker M, O’Halloran A, Anglin O, Burns E, et al. Hospitalizations associated with COVID-19 among children and adolescents—COVID-NET, 14 states, March 1, 2020–August 14, 2021. Morbidity and Mortality Weekly Report. 2021;70(36):1255.
6.Ward JL, Harwood R, Smith C, Kenny S, Clark M, Davis PJ, et al. Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year. Nature medicine. 2021:1-8.
7.Shi Q, Wang Z, Liu J, Wang X, Zhou Q, Li Q, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021;41:101155.
8.Lee SW, Ha EK, Yeniova AÖ, Moon SY, Kim SY, Koh HY, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021;70(1):76-84.
9.Mukkada S, Bhakta N, Chantada GL, Chen Y, Vedaraju Y, Faughnan L, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. The Lancet Oncology. 2021;22(10):1416-26.
10.Marlais M, Wlodkowski T, Vivarelli M, Pape L, Tönshoff B, Schaefer F, et al. The severity of COVID-19 in children on immunosuppressive medication. The Lancet Child & Adolescent Health. 2020;4(7):e17-e8.
11.Pedersen RN, Calzolari E, Husby S, Garne E. Oesophageal atresia: prevalence, prenatal diagnosis and associated anomalies in 23 European regions. Arch Dis Child. 2012 Mar;97(3):227-32.
12.Cassina M, Ruol M, Pertile R, Midrio P, Piffer S, Vicenzi V, et al. Prevalence, characteristics, and survival of children with esophageal atresia: A 32-year population-based study including 1,417,724 consecutive newborns. Birth Defects Res A Clin Mol Teratol. 2016 Jul;106(7):542-8.
13.Sulkowski JP, Cooper JN, Lopez JJ, Jadcherla Y, Cuenot A, Mattei P, et al. Morbidity and mortality in patients with esophageal atresia. Surgery. 2014;156(2):483-91.
14.Koumbourlis AC, Belessis Y, Cataletto M, Cutrera R, DeBoer E, Kazachkov M, et al. Care recommendations for the respiratory complications of esophageal atresia‐tracheoesophageal fistula. Pediatric Pulmonology. 2020;55(10):2713-29.
15.Yang C-F, Soong W-J, Jeng M-J, Chen S-J, Lee Y-S, Tsao P-C, et al. Esophageal atresia with tracheoesophageal fistula: ten years of experience in an institute. Journal of the Chinese Medical Association. 2006;69(7):317-21.
16.Shah R, Varjavandi V, Krishnan U. Predictive factors for complications in children with esophageal atresia and tracheoesophageal fistula. Diseases of the Esophagus. 2015;28(3):216-23.
17.van Lennep M, Singendonk MM, Dall’Oglio L, Gottrand F, Krishnan U, Terheggen-Lagro SW, et al. Oesophageal atresia. Nature Reviews disease primers. 2019;5(1):1-21.
18.Cartabuke RH, Lopez R, Thota PN. Long-term esophageal and respiratory outcomes in children with esophageal atresia and tracheoesophageal fistula. Gastroenterology report. 2016;4(4):310-4.
19.Somppi E, Tammela O, Ruuska T, Rahnasto J, Laitinen J, Turjanmaa V, et al. Outcome of patients operated on for esophageal atresia: 30 years’ experience. Journal of pediatric surgery. 1998;33(9):1341-6.
20.Porcaro F, Valfré L, Aufiero LR, Dall’Oglio L, De Angelis P, Villani A, et al. Respiratory problems in children with esophageal atresia and tracheoesophageal fistula. Italian Journal of Pediatrics. 2017;43(1):1-9.
21.Mousa H, Krishnan U, Hassan M, Dall’Oglio L, Rosen R, Gottrand F, et al. How to care for patients with EA-TEF: the known and the unknown. Current gastroenterology reports. 2017;19(12):1-15.
22.Flatrès C, Aumar M, Ley D, Sfeir R, Nicolas A, Bonnevalle M, et al. Prevalence of acid gastroesophageal reflux disease in infants with esophageal atresia/tracheoesophageal fistula. Pediatric Research. 2022;91(4):977-83.
23.Vergouwe FW, van Wijk MP, Spaander MC, Bruno MJ, Wijnen RM, Schnater JM, et al. Evaluation of gastroesophageal reflux in children born with esophageal atresia using pH and impedance monitoring. Journal of pediatric gastroenterology and nutrition. 2019;69(5):515.
24.Catalano P, Di Pace MR, Caruso AM, Casuccio A, De Grazia E. Gastroesophageal reflux in young children treated for esophageal atresia: evaluation with pH-multichannel intraluminal impedance. Journal of pediatric gastroenterology and nutrition. 2011;52(6):686-90.
25.Esposito S, Caramelli F, Principi N. What are the risk factors for admission to the pediatric intensive unit among pediatric patients with COVID-19? Italian Journal of Pediatrics. 2021;47(1):1-4.
26.Farrar DS, Drouin O, Hepburn CM, Baerg K, Chan K, Cyr C, et al. Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020—May 2021. medRxiv. 2022.
27.Pranata R, Huang I, Lawrensia S, Henrina J, Lim MA, Lukito AA, et al. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis. Pharmacological Reports. 2021;73(6):1642-9.